Hepatitis A Vaccine Market Growth Boosted by WHO 2030 Targets and Rising Global Travel

Hepatitis A Vaccine Market Size, Trends and Key Players

The hepatitis A vaccine market was estimated at US$ 742.31 million in 2023 and is projected to grow to US$ 948.16 million by 2034, rising at a compound annual growth rate (CAGR) of 2.25% from 2024 to 2034. The increasing outbreaks of hepatitis A, increasing awareness about immunization, and increase in travel and tourism.

Key Takeaways

• Asia-Pacific held a major revenue share of the market in 2024.
• North America is expected to grow at the fastest CAGR in the market during the forecast period.
• By type, the inactivated vaccine segment held the largest revenue share of the market in 2024.
• By type, the live attenuated vaccine segment is expected to grow with the highest CAGR in the market during the studied years.
• By application, the gove ment institution segment dominated the market in 2024.
• By application, the private sector segment is expected to show lucrative growth in the upcoming years.

Hepatitis A Vaccine Market: Boosting Immunity

The Hepatitis A vaccine prevents hepatitis A, an infectious liver disorder caused by the hepatitis A virus. It is given to children 12-23 months old as part of their routine childhood vaccination. The Centers for Disease Control and Prevention (CDC) recommends vaccinating people with chronic liver disease, treating people with clotting factor concentrates, working close to the virus, and living in communities where an outbreak is present. Hepatitis A vaccine is effective for at least twenty years or possibly a person’s entire life.

The increasing outbreaks of hepatitis A and rising incidences of HIV and chronic liver disease increase the need for hepatitis A vaccines. According to the WHO, around 354 million people globally are estimated to be suffering from hepatitis A, with 1.3 million deaths. Additionally, favorable gove ment policies and WHO guidelines for immunization boost the market.

Hepatitis A Vaccine Market Trends

• In December 2024, GlaxoSmithKline (GSK) plc announced a collaboration with Chongqing Zhifei Biological Products, Ltd. to revise the terms on which Zhifei will commercialize GSK’s shingles vaccines, Shingrix, in mainland China. Zhifei has exclusive rights to import, distribute, and co-promote the vaccine in mainland China till 2034.
• In January 2024, GSK Pharmaceuticals launched a multi-channel campaign to raise awareness about vaccinations to protect children of 1 to 2 years. The campaign encourages parents to continue the immunization schedule even in the 2nd year of their children’s lives to ensure continued protection.
• In April 2023, Sanofi launched its inactive hepatitis A vaccine, Avaxim Junior, for children aged 12 months to 15 years in the UK. The clinical trial data from 20 studies in 14 countries showed that the vaccine produced an effective response in two weeks in over 95% of individuals.
• GlaxoSmithKline plc demonstrated strong performance in the financial year 2023-24. The total 2023 sales were reported to be £30.3 billion. The total vaccine sales increased by 25%. The total operating profit was reported to be £6.7 billion.

Market Dynamics

Immunization Campaigns as a Driver

The major growth factor for the Hepatitis A vaccine market is the increasing immunization campaigns by gove ment and private agencies. The World Health Organization (WHO) strategizes to guide the health sector (2022-2030) to implement strategically focused responses to achieve the goals of ending AIDS, viral hepatitis, and sexually transmitted infections by 2030. Immunization programs create awareness among the general public to vaccinate their children. Some gove ment organizations in underdeveloped and developing countries provide free vaccinations to children from low-income groups.

Increasing Travel and Tourism: Opportunity for the Hepatitis A Vaccine Market

Hepatitis A is an inflammation of the liver caused by the hepatitis A virus, which can result in mild to severe illness. The virus is spread when an uninfected (or nonvaccinated) person ingests food or water contaminated with the feces of an infected person. Hence, the disease spreads due to unsafe water or food, inadequate sanitation, and poor personal hygiene. People traveling to multiple countries are at a higher risk of getting infected with the disease. The most prone geographical areas with a high risk of hepatitis A virus circulating in the local population include Africa (except South Africa), Easte Europe, and Asia. According to the United Nations report on tourism, an estimated 1.3 billion inte ational arrivals were reported in 2023. Most of the traveling was in the Middle East, Europe, and Africa. The CDC recommends that infants 6 through 11 months old traveling outside the US should receive one dose of hepatitis A vaccine, and adults with high traveling across various countries should also receive the vaccine.

Manufacturing Challenges Hinder the Hepatitis A Vaccine Market

Hepatitis A vaccine manufacturers face several challenges related to manufacturing. The high cost of hepatitis A vaccine manufacturing is attributed to the installation of necessary technology and favorable infrastructure. The demand for a balance between meeting global healthcare needs and minimizing environmental impact poses a significant challenge for sustainable manufacturing of hepatitis A vaccine. The scale-up of vaccine manufacturing requires huge amounts of antibodies, viral vectors, and pathogens. Also, the supply chain functioning for all essential components with proper cold chain logistics troubles the scale-up of vaccine manufacturing.

Regional Insights

Rising Incidences of Hepatitis A Dominated Asia-Pacific

Asia-Pacific dominated the hepatitis A vaccine market in 2023. The rising incidences of hepatitis A, favorable gove ment policies, increasing investments & collaborations, and increasing awareness drive the market. In India, over 2,400 confirmed cases and 18 confirmed deaths were reported as of May 2024. China reports 975 cases of hepatitis A as of January 2024. Asia-Pacific is the predominant region with a high epidemiology of hepatitis A. Several gove ment organizations in the region conduct immunization campaigns to spread awareness, thereby encouraging people to get a hepatitis A vaccination. The Indian Gove ment’s “Make in India” policy promotes indigenous manufacturing of hepatitis A vaccines. China is the only country developing, manufacturing, and distributing live attenuated hepatitis A vaccines. According to a WHO report, China represents one of the largest global demands (22%) for hepatitis A vaccines.

Presence of Key Players Drive the North American Market

North America is anticipated to grow fastest in the hepatitis A vaccine market during the forecast period. The presence of key players, state-of-the-art manufacturing infrastructure, and favorable gove ment policies drive the market. The major global players of hepatitis A vaccine manufacturers, such as GSK, Johnson & Johnson, and Merck, are located in the US. It was estimated that around 13 million doses of the total global demand of 37 million doses were utilized by 16 countries of The Regions of America (AMRO). The Canadian Gove ment provides free hepatitis A vaccines to infants, children, and adults at high risk of infection or spread of the virus. The National Advisory Committee on Immunization (NACI) serves as an advisory body on the use of vaccines in Canada. Hence, such gove ment organizations potentiate the market.

Segmental Insights

Which Type Segment Dominated the Hepatitis A Vaccine Market?

By type, the inactivated vaccine segment registered its dominance over the global. This segment dominated because the inactivated hepatitis A vaccine contains hepatitis A antigen inactivated virus. This promotes the body to produce antibodies against the antigen, developing immunity. These vaccines are more stable than the live ones. Also, they cannot convert into virulent forms, cause disease, and do not replicate. Hence, inactivated hepatitis A vaccines are widely preferred.

The live attenuated vaccine segment is expected to grow fastest in the hepatitis A vaccine market during the forecast period. Live attenuated hepatitis A vaccine contains a live, inactivated form of the virus. There are at least two live attenuated vaccines available globally in the market. It produces a robust immune response for long-lasting immunity.

Why Did the Gove ment Institution Segment Dominate the Hepatitis A Vaccine Market?

By application, the gove ment institution segment led the global market. This is due to gove ment institutions are at the forefront of providing vaccines at affordable costs. The gove ment conducts several immunization programs and awareness programs for hepatitis A vaccines.

The private sector segment is predicted to witness significant growth in the market over the forecast period. The private sector is an important contributor to immunization services. High capital investment by the private sector in manufacturing and distributing vaccines at a global scale boosts the segment growth.

Latest Announcement by Industry Leaders

Luke Miels, Chief Commercial Officer, GSK, commented that the revised agreement with Zhifei puts GSK’s collaboration on a sustainable footing, managing challenges in the macro environment in the near-term, and helping the company to reach even more Chinese people with its innovative adult vaccines over the long-term.

Recent Development in the Hepatitis A Vaccine Market

• In March 2025, Fortis Escorts announced the launch of a dedicated Vaccination Clinic to strengthen preventive healthcare and community well-being. It offers a comprehensive range of adult vaccinations, including influenza, Hepatitis A & B, pneumococcal, and typhoid.
• In September 2024, Indian Immunologicals (IIL) announced the launch of its pediatric dose of the indigenous Hepatitis A vaccine, Havisure (0.5 ml). IIL organized free Hepatitis A vaccination drives for children in two orphanages in Hyderabad and a health awareness session at an old-age home.
• In September 2024, Indian Immunologicals Limited (IIL) announced the launch of the pediatric dose of India’s first indigenous Hepatitis A vaccine, Havisure (0.5 ml). The launch strengthens IIL’s commitment to providing affordable and effective vaccines for all, especially children.
• In June 2022, the WHO released a new guideline, “Global Health Sector Strategy (GHSS) on viral hepatitis, 2022-2030,” to end the disease of viral hepatitis by 2030 globally.

Top Companies in the Hepatitis A Vaccine Market

• Changchun Institute of Biological Products
• GlaxoSmithKline plc
• Indian Immunologicals Limited
• Instituto Butantan
• Janssen Vaccines
• Johnson & Johnson
• KM Biologics
• Merck & Co., Inc.
• Mode a, Inc.
• Sanofi Pasteur S.A.
• Sinopharm
• Sinovac Biotech Ltd.
• Zerun Biotech

Segments Covered in the Report

By Type

• Inactivated Vaccine
• Live Attenuated Vaccine

By Application

• Gove ment Institutions
• Private Sectors
• Others

By Region

• North America
  • US
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait